- Home
- DCI vs AXSM Comparison
DCI vs AXSM Comparison
Compare DCI & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DCI | AXSM |
|---|---|---|
| Founded | 1915 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pollution Control Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 8.6B |
| IPO Year | 2005 | 2015 |
Fundamental Metrics
Financial Performance| Metric | DCI | AXSM |
|---|---|---|
| Price | $85.12 | $228.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 17 |
| Target Price | $99.00 | ★ $211.12 |
| AVG Volume (30 Days) | 515.9K | ★ 752.5K |
| Earning Date | 06-02-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.38% | N/A |
| EPS Growth | N/A | ★ 38.56 |
| EPS | ★ 1.75 | N/A |
| Revenue | ★ $2,844,900,000.00 | N/A |
| Revenue This Year | $4.58 | $57.24 |
| Revenue Next Year | $5.18 | $55.88 |
| P/E Ratio | $48.65 | ★ N/A |
| Revenue Growth | ★ 4.05 | N/A |
| 52 Week Low | $65.72 | $96.09 |
| 52 Week High | $112.84 | $234.29 |
Technical Indicators
Market Signals| Indicator | DCI | AXSM |
|---|---|---|
| Relative Strength Index (RSI) | 40.52 | 81.45 |
| Support Level | $82.75 | $148.87 |
| Resistance Level | $89.21 | N/A |
| Average True Range (ATR) | 2.10 | 10.02 |
| MACD | -0.12 | 3.46 |
| Stochastic Oscillator | 6.64 | 88.71 |
Price Performance
Historical ComparisonAbout DCI Donaldson Company Inc.
Donaldson is a leading manufacturer of filtration systems and replacement parts, including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors. The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.7 billion in revenue in its fiscal 2025.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.